Income StatementBalance SheetCash FlowSegments
Gilead Sciences logo

Gilead Sciences Cash Flow Statement

Operating, investing, and financing cash movements

Gilead Sciences generated $10.8B in operating cash flow over the trailing twelve months. After $576.0M in capital expenditures, free cash flow was $10.2B. Free cash flow increased 0.0% year-over-year. Based on the Q1 2026 filing.

Net Cash From Operating (TTM)$10.8BNet Cash From Investing (TTM)-$2.6BNet Cash From Financing (TTM)-$8.6BCapital Expenditures (TTM)$576.0MDepreciation And Amortization Cf (TTM)$1.4BNet Change In Cash (TTM)$2.4B
Latest FilingQ1 2026
Report Date2026-05-07
Market Cap$166.82B
P/E Ratio18.10
ROE43.19%

Operating

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Other non-cash income (expense)-$59.0M-$91.0M-$33.0M-$89.0M-$267.0M-$183.0M
Change in fair value of equity securities-$126.0M-$426.0M$142.0M$482.0M$253.0M$142.0M
Change in accounts payable—-$105.0M-$162.0M—-$95.0M-$67.0M
Change in accounts receivable-$72.0M-$79.0M$292.0M$333.0M—-$134.0M
Change in accrued liabilities$305.0M-$244.0M-$166.0M$811.0M—-$702.0M
Change in income taxes payable/receivable—-$552.0M-$1.3B-$122.0M-$134.0M-$29.0M
Change in inventories$226.0M$223.0M$175.0M$515.0M$123.0M$52.0M
Deferred income taxes-$379.0M-$199.0M-$178.0M$659.0M—$179.0M
Change in fair value of equity securities-$126.0M-$426.0M$142.0M$482.0M$253.0M$142.0M
Other Non-Cash Income (Expense)-$59.0M-$91.0M-$33.0M-$89.0M-$267.0M-$183.0M
Other Non-cash Income (Expense)-$59.0M-$91.0M-$33.0M-$89.0M-$267.0M-$183.0M
Other Non-cash Income (Expense)-$59.0M-$91.0M-$33.0M-$89.0M-$267.0M-$183.0M
Net cash from operating activities$3.0B$1.8B$827.0M$4.1B$3.3B$2.5B
Net income$1.8B$1.3B$2.0B$3.1B$2.2B$2.0B
Other non-cash income (expense)-$59.0M-$91.0M-$33.0M-$89.0M-$267.0M-$183.0M
Amortization$598.0M$599.0M$598.0M$596.0M$597.0M$596.0M
Depreciation$95.0M$97.0M$93.0M$90.0M$90.0M$93.0M
Increase (Decrease) in Prepaid Expense and Other Assets$146.0M-$12.0M-$81.0M$368.0M$36.0M-$5.0M
Other Noncash Income (Expense)-$59.0M-$91.0M-$33.0M-$89.0M-$267.0M-$183.0M
Acquired in-process research and development$0.0$253.0M$61.0M$170.0M$539.0M$107.0M
Other Non-cash Income and Expense-$59.0M-$91.0M-$33.0M-$89.0M-$267.0M-$183.0M
Other Non-Cash Adjustments-$59.0M-$91.0M-$33.0M-$89.0M-$267.0M-$183.0M
Other Non-Cash Income and Expense-$59.0M-$91.0M-$33.0M-$89.0M-$267.0M-$183.0M
Stock-based compensation$222.0M$209.0M$225.0M$230.0M$230.0M$218.0M

Investing

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Acquisitions, net of cash acquired$75.0M$273.0M$21.0M$167.0M$609.0M$109.0M
Sales of short-term available-for-sale investments—$0.0$295.0M$219.0M$340.0M$2.5B
Capital expenditures$147.0M$104.0M$107.0M$147.0M$205.0M$117.0M
Payment for (Proceeds from) Other Investing Activity-$35.0M$23.0M——-$11.0M$17.0M
Payments to Acquire Other Investments$39.0M$16.0M$21.0M$82.0M$14.0M$19.0M
Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale—$0.0$15.0M$17.0M$23.0M$36.0M
Sale of investments—$0.0$295.0M$219.0M$340.0M$2.5B
Net cash from investing activities-$225.0M-$415.0M-$2.1B-$427.0M-$1.8B$1.8B
Purchases of investments—$0.0$2.0B$270.0M$1.4B$525.0M

Financing

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Dividends paid$973.0M$1.0B$994.0M$1.0B$994.0M$1.0B
Other, net-$47.0M-$176.0M-$64.0M-$137.0M-$63.0M-$179.0M
Repayments of Debt$7.0M$1.8B$9.0M$9.0M$8.0M$2.8B
Payment of Deferred Purchase Consideration-$47.0M-$176.0M-$64.0M-$137.0M-$63.0M-$179.0M
Noncontrolling interest transactions and other-$47.0M-$176.0M-$64.0M-$137.0M-$63.0M-$179.0M
Net cash from financing activities—-$3.4B-$1.6B-$1.5B-$1.3B-$4.2B
Noncontrolling Interests Activity and Other-$47.0M-$176.0M-$64.0M-$137.0M-$63.0M-$179.0M
Proceeds from issuance of common stock$173.0M$252.0M$27.0M$97.0M$32.0M$166.0M
Repurchases of common stock$350.0M$730.0M$527.0M$435.0M$230.0M$419.0M

Free Cash Flow

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Free cash flow$2.8B$1.7B$720.0M$4.0B$3.1B$2.4B

Other

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Effect of exchange rate changes on cash-$55.0M$19.0M$73.0M$0.0$5.0M-$11.0M
Net increase (decrease) in cash$5.0B-$2.1B-$2.8B——$65.0M